Lyka Labs (BOM:500259) Other Operating Expense: ₹950 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500259 Lyka Labs Ltd BOM:500259
58 GF Score
Price ₹82.51
GF Value ₹129.76
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lyka Labs Other Operating Expense?

Lyka Labs BOM:500259 -1.77% 58 Other Operating Expense is ₹950 Mil as of Jun. 2026. GuruFocus rates BOM:500259 with a GF Score™ of 58/100 and a GF Value™ of ₹129.76 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Lyka Labs's Other Operating Expense for the three months ended in Jun. 2026 was ₹-0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹950 Mil.

Lyka Labs's quarterly Other Operating Expense stayed the same from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹0 Mil) but then declined from Mar. 2026 (₹0 Mil) to Jun. 2026 (₹-0 Mil).

Lyka Labs's annual Other Operating Expense increased from Mar. 2024 (₹1 Mil) to Mar. 2025 (₹3 Mil) but then declined from Mar. 2025 (₹3 Mil) to Mar. 2026 (₹0 Mil).

Lyka Labs Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Lyka Labs's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyka Labs Other Operating Expense Chart

Lyka Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.00 -0.56 0.95 2.86 0.00

Lyka Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00
BOM:500259
58GF Score
Lyka Labs Ltd BOM:500259
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyka Labs Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹950 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of ₹950 Mil mean?
Lyka Labs (BOM:500259) has a Other Operating Expense of ₹950 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Lyka Labs and its competitors.
Is Lyka Labs' Other Operating Expense too high?
Lyka Labs' current Other Operating Expense is ₹950 Mil. Overall, Lyka Labs has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Other Operating Expense compare to VRTX and REGN?
Lyka Labs' Other Operating Expense of ₹950 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Lyka Labs and its competitors. Lyka Labs's current Other Operating Expense is ₹950 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹129.76, compared to a current price of ₹82.51 — trading 36.4% below its estimated fair value. The current Other Operating Expense is ₹950 Mil. Lyka Labs' overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Other Operating Expense is ₹950 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyka Labs (BOM:500259) Overvalued in 2026?

Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued. The current stock price of ₹82.51 is trading 36.4% below its estimated GF Value™ of ₹129.76. GuruFocus considers Lyka Labs to be Significantly Undervalued.

Key valuation signals for BOM:500259:

  • Other Operating Expense: ₹950 Mil
  • GF Value™: ₹129.76 vs. price of ₹82.51 (36.4% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyka Labs Business Description

Other Exchanges LYKALABS:India
Address 30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
58GF Score

Get the complete analysis for BOM:500259

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹82.51
Price
₹129.76
GF Value